— Why it moved
Why VERU Stock Surged Today — June 4, 2026
Novo Nordisk agreed to hand Veru free Wegovy for a muscle-preservation trial, and a nine-day short cover queue turned a supply agreement into a 58% spike.
What moved VERU stock
Veru is the drug developer behind enobosarm, which its Phase 2b PLATEAU trial tests against the muscle loss that comes with GLP-1 drugs. Novo Nordisk agreed to supply Wegovy at no cost for that trial — not a buyout, not revenue, a clinical supply deal. The market treated it as validation of the obesity angle and paid up anyway.
The mechanics
A 13.7M float carried a genuinely crowded short book at nine days to cover. The stock more than tripled off its morning low before lunch, and 92.9M shares traded — the float turned over almost seven times.
VERU by the numbers
The alert window
Stock Pulse alerted mid-run at 12:11 PM at $4.63; the peak, $7.33, printed at 12:25 PM — fourteen minutes of window for a 58% move.
How VERU's move ended
The air came out immediately after the peak. The stock drifted lower all afternoon and closed at $4.23, 8.6% under the alert — the entire afternoon was a fade, and the close sat below where the alert fired. Free trial drug isn't revenue; Veru still has to fund and run the study itself. The catalyst was real, but the spike on top of it was momentum: when a nine-day cover queue is the fuel, the move ends when the covering does — fourteen minutes, in this case.